These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 27378345)

  • 21. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.
    Ribas A; Comin-Anduix B; Chmielowski B; Jalil J; de la Rocha P; McCannel TA; Ochoa MT; Seja E; Villanueva A; Oseguera DK; Straatsma BR; Cochran AJ; Glaspy JA; Hui L; Marincola FM; Wang E; Economou JS; Gomez-Navarro J
    Clin Cancer Res; 2009 Oct; 15(19):6267-76. PubMed ID: 19789309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma.
    Daly LE; Power DG; O'Reilly Á; Donnellan P; Cushen SJ; O'Sullivan K; Twomey M; Woodlock DP; Redmond HP; Ryan AM
    Br J Cancer; 2017 Jan; 116(3):310-317. PubMed ID: 28072766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ipilimumab in advanced melanoma: reports of long-lasting responses.
    Farolfi A; Ridolfi L; Guidoboni M; Nicoletti SV; Piciucchi S; Valmorri L; Costantini M; Scarpi E; Amadori D; Ridolfi R
    Melanoma Res; 2012 Jun; 22(3):263-70. PubMed ID: 22516968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The targeting of indoleamine 2,3 dioxygenase -mediated immune escape in cancer.
    Iversen TZ; Andersen MH; Svane IM
    Basic Clin Pharmacol Toxicol; 2015 Jan; 116(1):19-24. PubMed ID: 25207460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients.
    Seremet T; Koch A; Jansen Y; Schreuer M; Wilgenhof S; Del Marmol V; Liènard D; Thielemans K; Schats K; Kockx M; Van Criekinge W; Coulie PG; De Meyer T; van Baren N; Neyns B
    J Transl Med; 2016 Aug; 14(1):232. PubMed ID: 27484791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.
    Mauldin IS; Wages NA; Stowman AM; Wang E; Olson WC; Deacon DH; Smith KT; Galeassi N; Teague JE; Smolkin ME; Chianese-Bullock KA; Clark RA; Petroni GR; Marincola FM; Mullins DW; Slingluff CL
    Cancer Immunol Immunother; 2016 Oct; 65(10):1201-12. PubMed ID: 27522582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1.
    Block MS; Nevala WK; Pang YP; Allred JB; Strand C; Markovic SN
    Melanoma Res; 2019 Aug; 29(4):420-427. PubMed ID: 30520800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma.
    Gargett T; Abbas MN; Rolan P; Price JD; Gosling KM; Ferrante A; Ruszkiewicz A; Atmosukarto IIC; Altin J; Parish CR; Brown MP
    Cancer Immunol Immunother; 2018 Sep; 67(9):1461-1472. PubMed ID: 30014244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control.
    Robert C; Schadendorf D; Messina M; Hodi FS; O'Day S;
    Clin Cancer Res; 2013 Apr; 19(8):2232-9. PubMed ID: 23444228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma.
    Gyorki DE; Yuan J; Mu Z; Zaidi B; Pulitzer M; Busam K; Brady MS; Coit DG; Allison JP; Wolchok JD; Ariyan CE
    Ann Surg Oncol; 2013 Sep; 20(9):3106-11. PubMed ID: 23681603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ipilimumab (Yervoy) and the TGN1412 catastrophe.
    Bakacs T; Mehrishi JN; Moss RW
    Immunobiology; 2012 Jun; 217(6):583-9. PubMed ID: 21821307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.
    Weber JS; Hamid O; Chasalow SD; Wu DY; Parker SM; Galbraith S; Gnjatic S; Berman D
    J Immunother; 2012 Jan; 35(1):89-97. PubMed ID: 22130166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of concurrent immunoradiotherapy in patients with metastatic melanoma after progression on nivolumab.
    Nomura M; Otsuka A; Yoshimura M; Nonomura Y; Kaku Y; Matsumoto S; Muto M
    Cancer Chemother Pharmacol; 2018 May; 81(5):823-827. PubMed ID: 29502140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
    Weber J
    Oncologist; 2007 Jul; 12(7):864-72. PubMed ID: 17673617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy of melanoma.
    Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
    Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Vaccination therapy of melanoma].
    Schuler-Thurner B; Schuler G
    J Dtsch Dermatol Ges; 2005 Aug; 3(8):630-45. PubMed ID: 16033483
    [No Abstract]   [Full Text] [Related]  

  • 38. Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma.
    Peggs KS; Quezada SA
    Expert Rev Anticancer Ther; 2010 Nov; 10(11):1697-701. PubMed ID: 21080797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
    Davis ID; Chen Q; Morris L; Quirk J; Stanley M; Tavarnesi ML; Parente P; Cavicchiolo T; Hopkins W; Jackson H; Dimopoulos N; Tai TY; MacGregor D; Browning J; Svobodova S; Caron D; Maraskovsky E; Old LJ; Chen W; Cebon J
    J Immunother; 2006; 29(5):499-511. PubMed ID: 16971806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ipilimumab in the treatment of melanoma.
    Trinh VA; Hwu WJ
    Expert Opin Biol Ther; 2012 Jun; 12(6):773-82. PubMed ID: 22500861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.